Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis
Conclusions: The incidence of ipilimumab-related SAEs was higher in melanoma, the 10mg/kg group and during combination therapy. Clinicians should enhance awareness of these risk factors in clinical practice and carefully monitor patients.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Chang-Ying Guo, Si-Cong Jiang, Yu-Kang Kuang, Hao Hu Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Melanoma | Non-Small Cell Lung Cancer | Prostate Cancer | Skin Cancer | Small Cell Lung Cancer | Study | Yervoy